UPDATE 3-Catalent seeks slice of gene therapy market with Paragon buy
April 15, 2019 at 15:30 PM EDT
Contract drugmaker Catalent Inc said on Monday it would buy privately held Paragon Bioservices Inc for $1.2 billion in cash, bolstering its capabilities to make gene therapy drugs for its biotech clients.
